



14/12/2014

Direct Healthcare Professional Communication on restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing Irbesartan:

(Arena 150 & Arena 300 mg)

Dear Healthcare Professional,

Jamjoom Pharma would like to inform you about restrictions on combining different classes of medicines that act on the renin-angiotensin aldosterone system (RAAS), a hormone system that controls blood pressure and the volume of fluids in the body. This group of medicines (called RAAS-acting agents) has three main classes: angiotensin-receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACE-inhibitors) and direct renin inhibitors such as aliskiren. Combination of medicines from any two of these classes should not be used and, in particular, in patients with diabetes mellitus or renal impairment.

information on the safety Concern

- Combination therapy of direct renin inhibitors such as aliskiren with ACEI or ARB may cause an increased risk of hyperkalemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with diabetes mellitus or renal impairment.
- Combination therapy of ACEI and ARB drugs may cause an increased risk of hyperkalemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with diabetes mellitus or renal impairment.
- If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.

The information in this letter has been approved by the Saudi Food and Drug Authority.

The Summary of Products Characteristics (SPC) and Patient Information Leaflet (PIL) of Arena® (150 & 300 mg) in Saudi Arabia will be updated to reinforce the safety of treated patients.

1/2

مصنع جمجوم للأدوية
Jamjoom Pharmaceuticals

شركة مساهمة - رأس المال ١٠٠٠٠٠٠٠٠ ريال

عنوان المصنع: رقم القطعة م. ي ١ : ٢. المنطقة الصناعية، المرحلة الخامسة، جدة، ت: +٩٦٦ ١٢ ٦٠٨ ١١١١، ف: +٩٦٦ ١٢ ٦٠٨ ١٢٢٢

العنوان البريدي: ٦٢٦٧، جدة - ٢١٤٤٢، المملكة العربية السعودية، الإدارة: ت: +٩٦٦ ١٢ ٦١٤ ٠٠٩٩، ف: +٩٦٦ ١٢ ٦١٤ ٠٠٨٨

Factory Address: Plot No. ME1 : 3, Phase V, Industrial City, Jeddah, Tel.: + 966 12 608 1111, Fax: + 966 12 608 1222

Postal Address P.O.Box 6267, Jeddah 21442 Saudi Arabia, Administration: Tel.: + 966 12 614 0099, Fax: + 966 12 614 0088

E-mail : jpharma@jamjoompharma.com - Web Site : www.jamjoompharma.com



Call for reporting

As a reminder, there is a need to report any suspected adverse reactions to the National Pharmacovigilance and Drug Safety Center (NPC):

- Fax: +966-11-205-7662
- Call NPC at +966-11-2038222, Ext: 2317-2356-2353-2354-2334-2340.
- Toll free phone: 8002490000
- E-mail: npc.drug@sfd.gov.sa
- Website: www.sfd.gov.sa/npc

Pharmacovigilance department in Jamjoom Pharma):

- Fax: +966 12 6141199
- Email: ashar.naeem@jamjoompharma.com

Yours sincerely,



Dr. M Ashar Naeem
Pharmacovigilance Coordinator